Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer
この論文をさがす
説明
<jats:p>The current issue of <jats:italic>Cancer</jats:italic> includes a report on a concise, randomized controlled trial (RCT) with long‐term follow‐up that favors combined androgen blockade with bicalutamide versus lutenizing hormone‐releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate cancer. It has been 20 years since the first RCT on CAB was published, and the debate continues.</jats:p>
収録刊行物
-
- Cancer
-
Cancer 115 (15), 3376-3378, 2009-05-29
Wiley